Hepatitis C News

Hepatitis C treatment with Mavyret for 8 weeks had an overall sustained virologic response rate of 98% regardless of baseline patient or viral characteristics in a cohort of patients with genotypes 1 through 6, according to a recently published study.

To address the underlying opioid addiction that so often leads to injection-related infections, experts have suggested that directly treating the addiction should be a priority for ID specialists. We asked Peter Chin-Hong, MD, a professor of medicine at the University of California, San Francisco School of Medicine and Infectious Disease News Editorial Board member, if he agrees that ID specialists should treat opioid use disorder with medicine.

The opioid epidemic in the United States has affected millions, exposing them to health risks that include a range of infectious diseases.

A new hepatitis C virus finger-stick test can be used to diagnose infection in a single clinical visit, delivering results in 1 hour, according to researchers.

Recently published data showed that treatment outcomes did not differ between 8 weeks and 12 weeks of Harvoni among black patients with hepatitis C, contrary to guideline recommendations.

Recently published data showed no association between direct-acting antiviral therapy and an increased risk for hepatocellular carcinoma recurrence among liver transplantation candidates with hepatitis C who experienced initial complete response to local-regional therapy.

BOSTON — In this video, Christine M. Durand, MD, a transplant infectious diseases specialist at Johns Hopkins University School of Medicine, discusses the potential of using organs from donors with HIV or hepatitis C virus infection to address an “organ shortage crisis” in the United States.

Most patients with HIV who become infected with hepatitis C will not clear the infection spontaneously and face a chronic course, according to a study presented at the Conference on Retroviruses and Opportunistic Infections, also known as CROI. The researchers advocate for amended direct-acting drug labels and guidelines to allow usage of DAA therapy during the acute phase of HCV in high-risk individuals.

In Switzerland, men who have sex with men from other countries likely account for about one-quarter acute hepatitis C infections, according to a study presented at the Conference on Retroviruses and Opportunistic Infections, also known as CROI. The researchers recommend joint European scale-up schemes for DAA therapy.

Treatment with the direct-acting antiviral Zepatier for 8 weeks showed high efficacy among HIV-positive men who have sex with men infected with acute hepatitis C, according to study results presented at the Conference on Retroviruses and Opportunistic Infections, also known as CROI.